Nothing currently in dispute alters the fact that the industry groups agreed to a shift in the use of legal these terms which delivers a dramatic and probably irreversible expansion in the government's power to extract price reductions from companies with PBS-listed medicines.
Why would it take these powers if it did not intend to use them?
September 28, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia calls for Budget action to restore access to innovative medicines
February 3, 2026 - - Latest News -
Survey exposes deep gaps in support for Australians living with rare cancers
February 3, 2026 - - Latest News -
Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down
February 3, 2026 - - Latest News -
AusBiotech and Medicines Australia unite to accelerate advanced therapies
February 3, 2026 - - Latest News -
If you're going to pay for reforms, are these the changes you want to pay for?
February 3, 2026 - - Latest News -
Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy
February 2, 2026 - - Latest News -
AusBiotech urges adoption of national life sciences strategy as global competition intensifies
February 2, 2026 - - Australian Biotech

